Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 3

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Authors Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Published Date October 2008 Volume 2008:3(3) Pages 445—451

DOI http://dx.doi.org/10.2147/CIA.S2046

Published 2 October 2008

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Greece

Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.

Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition

Bostjan Humar, Les McNoe, Anita Dunbier, Rosemary Heathcott, Antony W Braithwaite, Anthony E Reeve

Biologics: Targets and Therapy 2008, 2:329-337

Published Date: 30 June 2008

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009

Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?

Dimitropoulos C, Hillas G, Nikolakopoulou S, Kostara K, Sagris K, Vlastos F, Alchanatis M

Cancer Management and Research 2011, 3:287-294

Published Date: 17 August 2011

Bactericidal activities of woven cotton and nonwoven polypropylene fabrics coated with hydroxyapatite-binding silver/titanium dioxide ceramic nanocomposite "Earth-plus"

Kasuga E, Kawakami Y, Matsumoto T, Hidaka E, Oana K, Ogiwara N, Yamaki D, Sakurada T, Honda  T

International Journal of Nanomedicine 2011, 6:1937-1943

Published Date: 9 September 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

An analysis of the Bateson Review of research using nonhuman primates

Greek R, Hansen LA, Menache A

Medicolegal and Bioethics 2011, 1:3-22

Published Date: 6 December 2011

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption

Zeng N, Gao X, Hu Q, Song Q, Xia H, Liu Z, Gu G, Jiang M, Pang Z, Chen H, Chen J, Fang L

International Journal of Nanomedicine 2012, 7:3703-3718

Published Date: 13 July 2012